AR087390A1 - Profarmacos de metilfenidato, procesos para su fabricacion y uso - Google Patents
Profarmacos de metilfenidato, procesos para su fabricacion y usoInfo
- Publication number
- AR087390A1 AR087390A1 ARP120102779A ARP120102779A AR087390A1 AR 087390 A1 AR087390 A1 AR 087390A1 AR P120102779 A ARP120102779 A AR P120102779A AR P120102779 A ARP120102779 A AR P120102779A AR 087390 A1 AR087390 A1 AR 087390A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryloxy
- haloalkyl
- arylsulfyl
- alkylaryl
- group
- Prior art date
Links
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 title abstract 4
- 229960001344 methylphenidate Drugs 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 31
- 125000001188 haloalkyl group Chemical group 0.000 abstract 22
- -1 heter oaryloxoxy Chemical group 0.000 abstract 11
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 5
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 5
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 4
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 150000001412 amines Chemical class 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 4
- 150000004715 keto acids Chemical class 0.000 abstract 4
- 125000005592 polycycloalkyl group Polymers 0.000 abstract 4
- 229920001223 polyethylene glycol Polymers 0.000 abstract 4
- 125000003107 substituted aryl group Chemical group 0.000 abstract 4
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000005089 alkenylaminocarbonyl group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000003282 alkyl amino group Chemical group 0.000 abstract 3
- 125000005210 alkyl ammonium group Chemical group 0.000 abstract 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 3
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 3
- 125000005018 aryl alkenyl group Chemical group 0.000 abstract 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 3
- 125000005100 aryl amino carbonyl group Chemical group 0.000 abstract 3
- 125000001769 aryl amino group Chemical group 0.000 abstract 3
- 125000004658 aryl carbonyl amino group Chemical group 0.000 abstract 3
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 3
- 125000005199 aryl carbonyloxy group Chemical group 0.000 abstract 3
- 125000004350 aryl cycloalkyl group Chemical group 0.000 abstract 3
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 3
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 3
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000005224 heteroarylcarbonylamino group Chemical group 0.000 abstract 3
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 abstract 3
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 abstract 3
- 125000005368 heteroarylthio group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052711 selenium Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 2
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 abstract 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 abstract 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 abstract 2
- 125000005164 aryl thioalkyl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000005095 alkynylaminocarbonyl group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 125000005015 aryl alkynyl group Chemical group 0.000 abstract 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 abstract 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000005110 aryl thio group Chemical group 0.000 abstract 1
- 125000000732 arylene group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 abstract 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
Abstract
Profármacos y composiciones para el tratamiento de diversas enfermedades y/o trastornos que comprenden metilfenidato o sus derivados, conjugados con al menos un alcohol, amina, oxoácido, tiol o sus derivados. En algunas formas de realización, los conjugados incluyen además al menos un conector. Esta tecnología también se refiere a la síntesis de metilfenidato o sus derivados, conjugados con al menos un alcohol, amina, oxoácido, tiol, o sus derivados o combinaciones. Acción sobre alteraciones del SNC.Reivindicación 1: Una composición de prodroga que comprende al menos un conjugado de metilfenidato con una estructura de la fórmula (1) o fórmula (2), donde X se selecciona entre el grupo que consiste en O, S, Se y NR1; donde Y se encuentra ausente o se selecciona entre el grupo que consiste en O, S, Se, NR2 y CR3R4; donde R1 y R2 se seleccionan en forma independiente entre el grupo que consiste en hidrógeno, alquenilo, alquenilaminocarbonilo, alcoxi, alcoxicarbonilo, alquilo, alquilamino, alquilaminocarbonilo, alquilamonio, alquilcarbonilo, alquilcarbonilamino, alquilcarboniloxi, alquilsulfinilo, alquilsulfonilo, alquiltio, alquinilo, alquinilaminocarbonilo, aminocarbonilo, arilo, arilo sustituido, arilalquenilo, arilalcoxi, arilalquilo, arilalquinilo, arilamino, arilaminocarbonilo, arilamonio, arilazo, arilcarbonilo, arilcarbonilamino, arilcarboniloxi, arilcicloalquilo, ariloxi, ariloxialquilo, arilsulfinilo, arilsulfinilalquilo, arilsulfonilo, arilsulfonilamino, ariltio, ariltioalquilo, cicloalquenilo, cicloalquenilalquilo, cicloalquilo, cicloalquilalquilo, cicloalquilamino, cicloalquiloxi, cicloalquinilo, cicloheteroalquilo, cicloheteroalquilalquilo, haloalcoxi, haloalquilo, heteroarilo, heteroarilalquenilo, heteroarilalquilo heteroarilamino, heteroarilcarbonilo, heteroarilcarbonilamino, heteroariloxo, heteroariloxi, heteroarilsulfinilo, heteroarilsulfonilo, heteroariltio, hidroxi, policicloalquenilo, policicloalquenilalquilo, policicloalquilo, policicloalquilalquilo, y polietilenglicol; donde R3 y R4 se seleccionan en forma independiente entre el grupo que consiste en hidrógeno, alquenilo, alquenilaminocarbonilo, alcoxi, alcoxicarbonilo, alquilo, alquilamino, alquilaminocarbonilo, alquilamonio, alquilcarbonilo, alquilcarbonilamino, alquilcarboniloxi, alquilsulfinilo, alquilsulfonilo, alquiltio, alquinilo, alquinilaminocarbonilo, amina, amino, aminocarbonilo, amonio, arilo, arilo sustituido, arilalquenilo, arilalcoxi, arilalquilo, arilalquinilo, arilamino, arilaminocarbonilo, arilamonio, arilazo, arilcarbonilo, arilcarbonilamino, arilcarboniloxi, arilcicloalquilo, ariloxi, ariloxialquilo, arilsulfinilo, arilsulfinilalquilo, arilsulfonilo, arilsulfonilamino, ariltio, ariltioalquilo, ciano, cicloalquenilo, cicloalquenilalquilo, carboxilo, cicloalquilo, cicloalquilalquilo, cicloalquilamino, cicloalquiloxi, cicloalquinilo, cicloheteroalquilo, cicloheteroalquilalquilo, halo, haloalcoxi, haloalquilo, heteroarilo, heteroarilalquenilo, heteroarilalquilo, heteroarilamino, heteroarilcarbonilo, heteroarilcarbonilamino, heteroariloxo, heteroariloxi, heteroarilsulfinilo, heteroarilsulfonilo, heteroariltio, hidroxi, nitro, oxo, policicloalquenilo, policicloalquenilalquilo, policicloalquilo, policicloalquilalquilo, polietilenglicol y tiol; donde L se encuentra ausente o es -[-A-Z-]n-; donde A se selecciona en forma independiente para cada subunidad repetida entre el grupo que consiste en CR5R6, arilo, arilo sustituido, arileno, carbociclo, cicloalquenilo, cicloalquilo, cicloalquinilo, heterociclo y heteroarilo; donde R5 y R6 se seleccionan en forma independiente entre sí y en forma independiente para cada subunidad repetida entre el grupo que consiste en hidrógeno, alquenilo, alquenilaminocarbonilo, alcoxi, alcoxicarbonilo, alquilo, alquilamino, alquilaminocarbonilo, alquilamonio, alquilcarbonilo, alquilcarbonilamino, alquilcarboniloxi, alquilsulfinilo, alquilsulfonilo, alquiltio, alquinilo, alquinilaminocarbonilo, amina, amino, aminocarbonilo, amonio, arilo, arilo sustituido, arilalquenilo, arilalcoxi, arilalquilo, arilalquinilo, arilamino, arilaminocarbonilo, arilamonio, arilazo, arilcarbonilo, arilcarbonilamino, arilcarboniloxi, arilcicloalquilo, ariloxi, ariloxialquilo, arilsulfinilo, arilsulfinilalquilo, arilsulfonilo, arilsulfonilamino, ariltio, ariltioalquilo, ciano, cicloalquenilo, cicloalquenilalquilo, carboxilo, cicloalquilo, cicloalquilalquilo, cicloalquilamino, cicloalquiloxi, cicloalquinilo, cicloheteroalquilo, cicloheteroalquilalquilo, halo, haloalcoxi, haloalquilo, heteroarilo, heteroarilalquenilo, heteroarilalquilo, heteroarilamino heteroarilcarbonilo, heteroarilcarbonilamino, heteroariloxo, heteroariloxi, heteroarilsulfinilo, heteroarilsulfonilo, heteroariltio, hidroxi, nitro, oxo, policicloalquenilo, policicloalquenilalquilo, policicloalquilo, policicloalquilalquilo, polietilenglicol y tiol; donde Z está ausente o se selecciona en forma independiente para cada subunidad repetida entre el grupo que consiste en O, S, Se y NH; donde n es 0 - 50; donde G se selecciona en forma independiente para cada subunidad repetida entre el grupo que consiste en alcohol, amina, aminoácido, amonio, oxoácido, péptido, poli(etilenglicol) (PEG), tiol, derivados de los mismos y combinaciones de los mismos; donde E es un oxoácido; y donde m es 0 - 5.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161512658P | 2011-07-28 | 2011-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR087390A1 true AR087390A1 (es) | 2014-03-19 |
Family
ID=47601775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120102779A AR087390A1 (es) | 2011-07-28 | 2012-07-30 | Profarmacos de metilfenidato, procesos para su fabricacion y uso |
Country Status (28)
Country | Link |
---|---|
US (4) | US9079928B2 (es) |
EP (2) | EP3189840B1 (es) |
JP (4) | JP5976111B2 (es) |
KR (5) | KR20180069934A (es) |
CN (2) | CN103826633B (es) |
AR (1) | AR087390A1 (es) |
AU (1) | AU2012286683C1 (es) |
BR (1) | BR112014002084B1 (es) |
CA (3) | CA2984544C (es) |
CL (1) | CL2014000210A1 (es) |
CO (1) | CO6900135A2 (es) |
DK (1) | DK2736510T3 (es) |
ES (2) | ES2883259T3 (es) |
HR (1) | HRP20170555T1 (es) |
HU (1) | HUE032113T2 (es) |
IL (5) | IL230650A (es) |
LT (1) | LT2736510T (es) |
MX (3) | MX362571B (es) |
MY (1) | MY162499A (es) |
PL (1) | PL2736510T3 (es) |
PT (1) | PT2736510T (es) |
RS (1) | RS55812B1 (es) |
RU (1) | RU2573835C2 (es) |
SG (1) | SG10201606225XA (es) |
SI (1) | SI2736510T1 (es) |
UA (1) | UA112654C2 (es) |
WO (1) | WO2013016668A2 (es) |
ZA (1) | ZA201308766B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2883259T3 (es) * | 2011-07-28 | 2021-12-07 | Kempharm Inc | Profármacos de metilfenidato, procesos para la obtención y uso de los mismos |
NZ722096A (en) | 2011-12-15 | 2016-11-25 | Alkermes Pharma Ireland Ltd | Prodrugs of secondary amine compounds |
ES2899694T3 (es) * | 2012-10-05 | 2022-03-14 | Sphaera Pharma Pte Ltd | Compuestos novedosos, su síntesis y sus usos |
WO2015001499A2 (en) * | 2013-07-04 | 2015-01-08 | Mahesh Kandula | Compositions and methods for the treatment of irritable bowel syndrome and the associated abdominal cramping |
CN104418797B (zh) * | 2013-08-26 | 2019-04-19 | 上海医药集团股份有限公司 | 哌甲酯、右哌甲酯的制备方法、其中间体及制备方法 |
US20170056352A1 (en) | 2015-08-25 | 2017-03-02 | Rgenix, Inc. | PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF |
CN108348775B (zh) * | 2015-09-15 | 2021-07-02 | 普瑞西斯生物学研究有限责任公司 | 芬坎法明的前药 |
ES2942285T3 (es) | 2016-10-31 | 2023-05-31 | Biocryst Pharm Inc | Profármacos de inhibidores de la calicreína |
WO2018107131A1 (en) * | 2016-12-11 | 2018-06-14 | Kempharm, Inc. | Methylphenidate-prodrugs, processes of making and using the same |
NZ754751A (en) | 2016-12-11 | 2022-05-27 | Kempharm Inc | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
WO2018160178A1 (en) | 2017-03-01 | 2018-09-07 | Rgenix, Inc. | Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof |
EP3609482A4 (en) * | 2017-04-11 | 2021-01-13 | John K. Thottathil | NEW ALPHA-HYDROXY CARBOXYLIC ACID AND DERIVATIVES AND OTHER MEDICINAL PRODUCTS FAT-TYPE AMID AND IMIDE OF AMPHETAMINE COMPOUNDS AND THEIR USES |
US11975039B2 (en) | 2018-05-10 | 2024-05-07 | Helixmith Co., Ltd. | Herbal composition for treatment of attention deficit hyperactivity disorder |
WO2020067507A1 (ja) * | 2018-09-28 | 2020-04-02 | 生化学工業株式会社 | 第1級アミン化合物又は第2級アミン化合物-酸性多糖コンジュゲートとその製造方法 |
US11174229B2 (en) * | 2018-10-29 | 2021-11-16 | Kempharm, Inc. | D-amphetamine compounds, compositions, and processes for making and using the same |
TW202404581A (zh) | 2022-05-25 | 2024-02-01 | 美商醫肯納腫瘤學公司 | Mek抑制劑及其用途 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4428935A (en) * | 1982-05-24 | 1984-01-31 | Pfizer Inc. | Penicillanic acid dioxide prodrug |
US6210705B1 (en) * | 1997-12-15 | 2001-04-03 | Noven Pharmaceuticals, Nc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
WO1999036403A1 (en) * | 1998-01-13 | 1999-07-22 | The Trustees Of The University Of Pennsylvania | Novel dopamine re-uptake inhibitors and methods of synthesizing and using the same |
US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
JP2004501067A (ja) * | 2000-01-28 | 2004-01-15 | ローム アンド ハース カンパニー | 高められた特性をもつ医薬 |
US20020132793A1 (en) * | 2000-08-28 | 2002-09-19 | Mel Epstein | Use of methylphenidate compounds to enhance memory |
EP1315495A2 (en) * | 2000-08-28 | 2003-06-04 | Sention, Inc. | Use of threo-methylphenidate compounds to enhance memory |
US7700561B2 (en) | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
WO2004080959A2 (en) * | 2003-03-07 | 2004-09-23 | Isp Investments Inc. | Process for the preparation of dexmethylphenidate hydrochloride |
FI120187B (fi) * | 2003-03-14 | 2009-07-31 | Outotec Oyj | Menetelmä prosessin säätämiseksi |
CA2585014A1 (en) * | 2004-10-22 | 2006-05-04 | Mark Froimowitz | Methylphenidate analogs and methods of use thereof |
US8163701B2 (en) | 2005-08-19 | 2012-04-24 | Signature Therapeutics, Inc. | Prodrugs of active agents |
MX2009006007A (es) * | 2006-12-05 | 2009-07-17 | Neurogesx Inc | Profarmacos y metodos para hacer y usar los mismos. |
JP2010512413A (ja) * | 2006-12-11 | 2010-04-22 | ケムファーム・インコーポレーテッド | アンフェタミンの非標準アミノ酸結合体およびそれらの製造方法および使用方法 |
CA2677241A1 (en) * | 2007-02-02 | 2008-08-14 | Colucid Pharmaceuticals, Inc. | Compounds that inhibit cholinesterase |
CN101631770A (zh) * | 2007-02-02 | 2010-01-20 | 科露西德医药品公司 | 抑制胆碱酯酶的化合物 |
AU2008213643A1 (en) | 2007-02-08 | 2008-08-14 | Kempharm, Inc. | Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same |
US20100145057A1 (en) * | 2007-03-15 | 2010-06-10 | Sun Pharma Advanced Research Company Ltd. | Novel prodrugs |
RU2470021C2 (ru) * | 2007-05-23 | 2012-12-20 | Мерк Шарп Энд Домэ Корп. | Пиридилпиперидиновые антагонисты рецептора орексинов |
US20090048229A1 (en) * | 2007-07-18 | 2009-02-19 | Rupniak Nadia M J | Methods for promoting wakefulness |
US8318813B2 (en) | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
ES2883259T3 (es) | 2011-07-28 | 2021-12-07 | Kempharm Inc | Profármacos de metilfenidato, procesos para la obtención y uso de los mismos |
NZ722096A (en) | 2011-12-15 | 2016-11-25 | Alkermes Pharma Ireland Ltd | Prodrugs of secondary amine compounds |
-
2012
- 2012-07-27 ES ES17157635T patent/ES2883259T3/es active Active
- 2012-07-27 SI SI201230904A patent/SI2736510T1/sl unknown
- 2012-07-27 KR KR1020187017033A patent/KR20180069934A/ko active Application Filing
- 2012-07-27 UA UAA201402019A patent/UA112654C2/uk unknown
- 2012-07-27 WO PCT/US2012/048641 patent/WO2013016668A2/en active Application Filing
- 2012-07-27 PT PT128174232T patent/PT2736510T/pt unknown
- 2012-07-27 KR KR1020167010571A patent/KR101869885B1/ko active IP Right Grant
- 2012-07-27 PL PL12817423T patent/PL2736510T3/pl unknown
- 2012-07-27 MX MX2016010664A patent/MX362571B/es unknown
- 2012-07-27 SG SG10201606225XA patent/SG10201606225XA/en unknown
- 2012-07-27 KR KR1020197020055A patent/KR20190085184A/ko not_active Application Discontinuation
- 2012-07-27 RS RS20170338A patent/RS55812B1/sr unknown
- 2012-07-27 BR BR112014002084-1A patent/BR112014002084B1/pt active IP Right Grant
- 2012-07-27 KR KR1020137034565A patent/KR101616111B1/ko active IP Right Grant
- 2012-07-27 MX MX2013015088A patent/MX341416B/es active IP Right Grant
- 2012-07-27 HU HUE12817423A patent/HUE032113T2/en unknown
- 2012-07-27 JP JP2014523083A patent/JP5976111B2/ja active Active
- 2012-07-27 CA CA2984544A patent/CA2984544C/en active Active
- 2012-07-27 CA CA2837732A patent/CA2837732C/en active Active
- 2012-07-27 CN CN201280037735.0A patent/CN103826633B/zh active Active
- 2012-07-27 ES ES12817423.2T patent/ES2621306T3/es active Active
- 2012-07-27 KR KR1020197020054A patent/KR20190085183A/ko not_active Application Discontinuation
- 2012-07-27 EP EP17157635.8A patent/EP3189840B1/en active Active
- 2012-07-27 RU RU2014107678/04A patent/RU2573835C2/ru active
- 2012-07-27 US US14/234,440 patent/US9079928B2/en active Active
- 2012-07-27 DK DK12817423.2T patent/DK2736510T3/en active
- 2012-07-27 LT LTEP12817423.2T patent/LT2736510T/lt unknown
- 2012-07-27 CN CN201710268246.0A patent/CN107261148B/zh active Active
- 2012-07-27 MY MYPI2013004688A patent/MY162499A/en unknown
- 2012-07-27 EP EP12817423.2A patent/EP2736510B1/en active Active
- 2012-07-27 CA CA3123900A patent/CA3123900A1/en active Pending
- 2012-07-27 AU AU2012286683A patent/AU2012286683C1/en active Active
- 2012-07-30 AR ARP120102779A patent/AR087390A1/es active IP Right Grant
-
2013
- 2013-11-21 ZA ZA2013/08766A patent/ZA201308766B/en unknown
- 2013-12-02 CO CO13282303A patent/CO6900135A2/es not_active Application Discontinuation
- 2013-12-18 MX MX2019001093A patent/MX2019001093A/es active IP Right Grant
-
2014
- 2014-01-26 IL IL230650A patent/IL230650A/en active IP Right Grant
- 2014-01-28 CL CL2014000210A patent/CL2014000210A1/es unknown
-
2015
- 2015-06-01 US US14/727,498 patent/US9453037B2/en active Active
-
2016
- 2016-06-28 IL IL246503A patent/IL246503A/en active IP Right Grant
- 2016-07-15 JP JP2016139995A patent/JP6272403B2/ja active Active
- 2016-08-26 US US15/249,088 patent/US10231960B2/en active Active
-
2017
- 2017-04-05 HR HRP20170555TT patent/HRP20170555T1/hr unknown
- 2017-08-24 IL IL254143A patent/IL254143B/en active IP Right Grant
- 2017-12-28 JP JP2017253020A patent/JP6505822B2/ja active Active
-
2018
- 2018-10-21 IL IL26249318A patent/IL262493B/en active IP Right Grant
-
2019
- 2019-01-10 US US16/244,460 patent/US20190142815A1/en not_active Abandoned
- 2019-03-26 JP JP2019058283A patent/JP6731090B2/ja active Active
- 2019-09-12 IL IL269322A patent/IL269322B/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR087390A1 (es) | Profarmacos de metilfenidato, procesos para su fabricacion y uso | |
UY31524A1 (es) | Nuevos compuestos 010 | |
AR064842A1 (es) | Pirrolidin-2-onas, y su uso en la preparacion de inhibidores de nep | |
CO6210735A2 (es) | Antagonistas de la ruta de hedgehog y aplicaciones terapeuticas de los mismos | |
ECSP055671A (es) | Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa | |
PA8623101A1 (es) | Compuestos farmaceuticamente activos | |
BRPI0507065A (pt) | derivados de quinolina e seu uso como inibidores micobacterianos | |
AR069364A1 (es) | Derivados heterociclicos que modulan la miosina del musculo liso y/o la miosina no muscular y composiciones farmaceuticas que los contienen | |
CO6260076A2 (es) | Derivados de uracilo o timina para el tratamiento de la hepatitis c | |
CR11518A (es) | Compuestos de carbamoilo como inhibidores de dgat1 190 | |
PE20120106A1 (es) | Moduladores de receptores tipo toll | |
EA200701176A1 (ru) | Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их | |
PE20030865A1 (es) | Composiciones farmaceuticas para inhibidores de proteasa viral de la hepatitis c | |
ATE431333T1 (de) | Amino-propanolderivate | |
ES2496592T3 (es) | Proceso para la preparación de Imatinib y compuestos intermedios del mismo | |
BRPI0407306A (pt) | 1,2,4- triazinas de inibição de hiv | |
PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
UY29510A1 (es) | Derivados de urea, metodos para su fabricación, y usos de los mismos | |
MX2007007025A (es) | Nuevos derivados de hidantoina como inhibidores de metaloproteinasa. | |
MX2012006805A (es) | Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa. | |
UY32336A (es) | Nuevos compuestos de acido 2-({ [(1Z)-1-2(2-amino-1,3-tiazol-4-il)-2-{ [(3S)-1-({ [5-hidroxi-4-oxo-1,4-dihidropiridin-2-il)-5-oxo-4-propil-4, 5 - dihidro - 1H - 1, 2, 4 - trialzol - 1 - il]sulfonil} carbamoil) -2 - oxazetidin -3 -il] amino} - 2 - oxoetiliden] amino} oxi) - 2 - metilpropanoico, composiciones farmacéuticas conteniendolos y aplicaciones. | |
MY137468A (en) | Use of biguanide derivatives to manufacturing a medicinal product with cicatrizing action | |
UY29768A1 (es) | Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones | |
AR084978A1 (es) | Metodo y composicion para suministrar ingrediente activo al aire y su uso | |
AR063625A1 (es) | COMPUESTOS HETEROCICLICOS eTILES COMO AGENTES ANTICANCEROSOS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |